2Hudson LD. Monti CM. Rational and use of corticosteroids in chronic obstructive pulmonary disease. Med Clin North Am,1990,74:661.
3Szafranski W,Cukier A,Ramirez A,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 2003,21 (1): 74-81,
4Barnes P. Scientific rationale for inhaled combination therapy with long-acting β2-agonist and corticosteroids. Eur Respir J,2002,19(1): 182-191.
5Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucoorticoids and β2-agonist on bronchial airway smooth muscle cell through synchronized cellular signaling. Lancet, 2002,360(9342): 1293-1299.
6Senderovitz T, Vestbo J,Frandsen N,et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med, 1999,93(10):715-718.
7van Grunsven P, van Schayck C, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease:a meta analysis. Thorax,1999,54(1):7-14.
8Abdullah A,Sin DD,McAlister FA,et al. The Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A Systematic Review of Randomized Placebo-Controlled Trials.Am J Med,2002,113(1):59-65.
9Highland KB,Stvarge C,Heffaver JE,et al. Long-Term Effects of Inhaled Corticosteroids on FEV1 in Patients with Chronic Obstructive Pulmonary Disease. Ann Intern Med, 2003, 138(12) :969-973.
10Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflowlimitation in chronic obstructive pulmonary disease: a meta analysis. Thorax,2003,58(11) :937-941.
